Pacira BioSciences (PCRX) director receives grant of 39,291 stock options

Rhea-AI Filing Summary

Pacira BioSciences, Inc. director Samit Hirawat received a grant of stock options on January 27, 2026. The award covers 39,291 stock options with an exercise price of $19.85 per share, held directly, and represents a right to buy common stock.

According to the vesting terms, one-third of the options vest on the first anniversary of the grant date. The remaining options vest in equal monthly installments over the following two years, as long as the director continues in service. The options expire on January 27, 2036.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hirawat Samit

(Last) (First) (Middle)

C/O PACIRA BIOSCIENCES, INC.

2000 SIERRA POINT PARKWAY, SUITE 900

(Street)

BRISBANE CA 94005

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Pacira BioSciences, Inc. [ PCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$19.85	01/27/2026		A		39,291		(1)	01/27/2036	Common Stock	39,291	$0	39,291	D

Explanation of Responses:

1. The stock option vests and becomes exercisable as to one-third of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal monthly installments over the subsequent two years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

Remarks:

	/s/ Kristen Williams, Attorney-in-Fact	01/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Pacira BioSciences (PCRX) report in this Form 4 for Samit Hirawat?

Pacira BioSciences reported that director Samit Hirawat received 39,291 stock options on January 27, 2026. These options are a right to buy common stock at an exercise price of $19.85 per share, held directly by the director.

How many Pacira BioSciences stock options were granted to Samit Hirawat?

The filing shows a grant of 39,291 stock options to director Samit Hirawat. These options are reported as derivative securities, giving the right to purchase common stock, with 39,291 derivative securities beneficially owned following the transaction.

What is the exercise price and expiration date of Samit Hirawat’s Pacira options?

The stock options granted to Samit Hirawat have an exercise price of $19.85 per share and expire on January 27, 2036. They are structured as a right to buy Pacira BioSciences common stock if exercised before the expiration date.

What is the vesting schedule for Samit Hirawat’s Pacira BioSciences option grant?

The options vest one-third on the first anniversary of the January 27, 2026 grant date. The remaining two-thirds vest in equal monthly installments over the subsequent two years, provided Samit Hirawat remains in continuous service with Pacira BioSciences.

Is Samit Hirawat’s Pacira option grant reported as directly or indirectly owned?

The Form 4 reports direct ownership of the 39,291 stock options by Samit Hirawat. The ownership form is listed as “D” for direct, and there is no separate entity or indirect nature of beneficial ownership disclosed in this filing.

Did Pacira BioSciences report any purchase or sale of common stock in this Form 4?

The filing reports an option grant, not a purchase or sale of existing common shares. It discloses 39,291 stock options, a right to buy Pacira BioSciences common stock in the future, with no separate common stock transaction listed in Table I.